Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 extension study of a third dose of MenABCWY formulations or rMenB in previously vaccinated adolescents
2014-005014-36Phase 2
- Sponsor
- Novartis
- Start
- Nov 2014
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of meningococcal group A, B, C, W and Y vaccine, meningococcal group B vaccine, tdap vaccine in meningococcal disease, meningococcal meningitis, meningococcemia, sponsored by Novartis.
02
Drugs
meningococcal group A, B, C, W and Y vaccinemeningococcal group B vaccinetdap vaccine
03
Conditions
meningococcal diseasemeningococcal meningitismeningococcemia
Beyond the preview
Go deeper on 2014-005014-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005014-36.